Nul raised a $1M seed in 2026 for a UK telehealth programme to cut drinking

UK telehealth platform for alcohol reduction combining clinical care, prescription medication and behavioural support

A discreet subscription pairing prescription naltrexone, clinicians and digital guidance can serve drinkers who want to reduce, not quit

$1 million seed led by dmg ventures and BYVP with angel investors

Nul, founded by Matus Maar, is a UK healthtech startup building a supported alcohol reduction platform. Its programme is based on naltrexone, a medication used to reduce alcohol cravings, delivered through a fully remote subscription with virtual consultations, ongoing clinical support and structured digital guidance based on The Sinclair Method.

Nul launched a UK test phase in summer 2025 and says it onboarded more than 120 paying customers, reaching an annualised revenue run rate above £300,000 within its first months, driven largely by organic demand and word-of-mouth. These figures are the company's own.

In February 2026 Nul raised $1M in seed funding to support its full UK commercial launch, grow its clinical and product teams, scale customer acquisition and prepare for international expansion including the US. It also planned a crowdfunding campaign on Republic Europe so retail investors could join the round.

Alcohol harm affects millions, yet treatment options have seen limited innovation

Telehealth and online pharmacy had already changed weight loss and mental health

Many drinkers want to reduce rather than stop, which a naltrexone programme allows

Early demand was organic, giving the company evidence to raise seed funding

Telehealth models that worked for weight loss can be tried in other categories; early organic demand is a useful signal, but retention and outcomes still have to be shown.

As of 2026-02-16, Nul had a $1M seed, 120+ paying customers and a £300,000 annualised run rate by its own count, and was preparing a full UK launch and a crowdfunding round.